Evidence map›Paper›PMID 38532280›Full record

Observational studyActa obstetricia et gynecologica Scandinavica2024

Procalcitonin and C-reactive protein as early markers of anastomotic leakage in intestinal resections for advanced ovarian cancer (EDMOCS).

José Luis Sánchez-Iglesias, Clara Morales-Coma, Lucas Minig, Víctor Lago, Santiago Domingo, Gemma Mancebo, Jaime Siegrist, María Soledad Fidalgo García, Antoni Llueca, Anna Serra and 9 more

Open access · diamondAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Acta obstetricia et gynecologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 1 country.

José Luis Sánchez-IglesiasDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-4542-3969
Clara Morales-ComaBreast Pathology Unit, Vall d'Hebron University Hospital, Barcelona, Spain.
Lucas MinigDepartment of Gynecologic Oncology, IMED Hospital, Valencia, Spain.
Víctor LagoDepartment of Gynecology, CEU Cardenal Herrera University, Valencia, Spain.ORCID 0000-0002-2971-1899
Santiago DomingoDepartment of Gynecologic Oncology, La Fe University Hospital, Valencia, Spain.
Gemma ManceboGynecological Cancer Multidisciplinary Unit, Hospital del Mar, Barcelona, Spain.
Jaime SiegristOncologic Gynecology Unit, Department of Gynecology, La Paz University Hospital, Madrid, Spain.
María Soledad Fidalgo GarcíaDepartment of Gynecologic Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Antoni LluecaMultidisciplinary Unit of Abdominal Pelvic Oncology Surgery, Hospital General Universitario de Castellon, Castellón, Spain.ORCID 0000-0003-3723-8795
Anna SerraMultidisciplinary Unit of Abdominal Pelvic Oncology Surgery, Hospital General Universitario de Castellon, Castellón, Spain.
Paloma Cobas LozanoDepartment of Gynecologic Oncology, Hospital Universitario Donostia, OSI Donostialde, Donostia, Spain.
Arantza Lekuona ArtolaDepartment of Gynecologic Oncology, Hospital Universitario Donostia, OSI Donostialde, Donostia, Spain.
Natalia R Gómez-HidalgoDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Úrsula AcostaDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0001-8887-544X
Roser Ferrer-CostaDepartment of Biochemistry, Vall d'Hebron University Hospital, Barcelona, Spain.
Melissa BradburyDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Assumpció Pérez-BenaventeDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Antonio Gil-MorenoDepartment of Gynecologic Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0003-1106-5590
SEGO Spain‐GOG Group
Vall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ESDonostiako Unibertsitate Ospitalea · ESUniversidad Cardenal Herrera CEU · ESUniversitat Jaume I · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario Central de Asturias · ESHospital Universitario La Paz · ESUniversitat Pompeu Fabra · ES

Funding

Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
6 · The paper itself

Abstract

introductionSerum levels of procalcitonin and C-reactive protein (CRP) have been used to predict anastomotic leakage after colorectal surgery, but information is scarce in advanced ovarian cancer (AOC) surgery with bowel resection. This study aimed to assess the predictive value of procalcitonin and CRP in detecting anastomotic leakage after AOC surgery with bowel resection. The study also aimed to determine the optimal postoperative reference values and the best day for evaluating these markers. MATERIAL AND

methodsThis prospective, observational and multicentric trial included 92 patients with AOC undergoing debulking surgery with bowel resection between 2017 and 2020 in 10 reference hospitals in Spain. Procalcitonin and CRP levels were measured at baseline and on postoperative days 1-6. Receiver operating characteristic analysis was performed to evaluate the predictive value of procalcitonin and CRP at each postoperative day. Sensitivity, specificity, positive and negative predictive values were calculated.

resultsAnastomotic leakage was detected in six patients (6.5%). Procalcitonin and CRP values were consistently higher in patients with anastomotic leakage at all postoperative days. The maximum area under the curve (AUC) for procalcitonin was observed at postoperative day 1 (AUC = 0.823) with a cutoff value of 3.8 ng/mL (83.3% sensitivity, 81.3% specificity). For CRP, the maximum AUC was found at postoperative day 3 (AUC = 0.833) with a cutoff level of 30.5 mg/dL (100% sensitivity, 80.4% specificity).

conclusionsProcalcitonin and C-reactive protein are potential biomarkers for early detection of anastomotic leakage after ovarian cancer surgery with bowel resection. Further prospective studies with a larger sample size are needed to confirm these findings.

Indexed as

Anastomotic LeakC-Reactive ProteinOvarian NeoplasmsProcalcitoninAdultAgedBiomarkersBiomarkers, TumorCytoreduction Surgical ProceduresFemaleHumansMiddle AgedPredictive Value of TestsProspective StudiesSpainBiomarkersBiomarkers, TumorC-Reactive ProteinProcalcitoninanastomotic leakagecolorectal resectionovarian cancer

Identifiers

PMID38532280
PMCPMC11168259
OpenAlexW4393229442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.